Cybin Inc. announced that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine ("DMT") has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The CYB004-E Phase 1 trial was acquired from Entheon Biomedical Corp. ("Entheon") in July 2022.

The CYB004-E trial marks one of a number of strategic transactions that Cybin has completed in recent months to support its research and development pipeline of active psychedelic-based programs and potential future novel drug candidates. The acquisition of the CYB004-E Phase 1 trial replaced Cybin's planned pilot study that was expected to commence in the third quarter of 2022, and as such, has served to potentially accelerate the clinical development path of CYB004, the Company's proprietary deuterated DMT molecule for the potential treatment of anxiety disorders. The CYB004-E trial is ongoing at the Centre for Human Drug Research in the Netherlands and is the Company's largest Phase 1 DMT trial conducted to date.

The study is assessing the pharmacokinetics and pharmacodynamics of DMT and is anticipated to provide safety and dosing data to inform the clinical development plan for CYB004. Cybin expects the Phase 1 trial to be completed in the first half of 2023.